|
| 產(chǎn)地 | France |
| 保存條件 | 2-8 ℃ |
| 品牌 | AntibodySystem |
| 貨號 | KDD30801 |
| 用途 | For Research Use Only. |
| 檢測方法 | Elisa |
| CAS編號 | |
| 保質(zhì)期 | 1 year |
| 適應物種 | Indatuximab |
| 檢測限 | 0.156 ug /ml |
| 數(shù)量 | 99999 |
| 包裝規(guī)格 | 96 assays |
| 標記物 | Unconjugate |
| 純度 | 95%% |
| 樣本 | Plasma, Serum |
| 應用 | Elisa |
| 是否進口 | 否 |
KDD30801
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Colorimetric
CV<20%
Plasma, Serum
Quantitative
0.156 μg/ml
0.31-5 μg/mL
80-120%
Indatuximab
BT-062, nBT062-DM4, Indatuximab ravtansine(1238517-16-2)
Indatuximab ravtansine (BT062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (CD138-specific antibody), which is covalently conjugated to the maytansinoid drug DM4 via a disulfide bond-based linker. Maytansinoids are structural analogs of the cytotoxic agent maytansine, which has been evaluated in phase I and phase II clinical trials. They exhibit anti-mitotic activity by inducing metaphase arrest of dividing cells, causing cell death. Upon internalization of indatuximab ravtansine by target tumor cells, lysosomal processing of the disulfide linker generates a lysine metabolite which is reduced and S-methylated producing the lipophilic and cytotoxic metabolite, S-methyl-DM4. The mechanism of action of indatuximab ravtansine resembles that of trastuzumab emtansine, an antibody-drug conjugate indicated for HER2-positive metastatic breast cancer which uses the HER2-targeting properties of trastuzumab to deliver the cytotoxic DM1 within the cell by means of a stable linker. The intracellular drug delivery to target tumor cells can improve the therapeutic index of the cytotoxic drug and minimize exposure of normal tissue. Indatuximab ravtansine has previously been shown in vivo in multiple myeloma mouse xenograft models to significantly inhibit tumor growth and prolong host survival without any toxicity signals. Based on these preclinical results, a phase I clinical trial of indatuximab ravtansine demonstrated the first signs of clinical activity in patients with relapsed or refractory multiple myeloma without any toxicity signals. Furthermore, preliminary data from a phase I/IIa study in relapsed or refractory multiple myeloma indicated that indatuximab ravtansine is well tolerated even in a multiple-dose schedule and provided further evidence of clinical activity. Indatuximab ravtansine is being investigated as part of a treatment for multiple myeloma.
2-8 ℃
For Research Use Only.
Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.
AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗的 創(chuàng)立于法國,專注于生命科學和生物制藥領域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。
普健生物作為AntibodySystem在亞洲區(qū)授權 ,致力于為廣大科研工作者提供 的產(chǎn)品服務。
如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。
以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準
